Sdz-wag-994

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 125480

CAS#: 130714-47-5

Description: SDZ-WAG-994 is a potent and selective A1 receptor agonist.

Chemical Structure

img
Sdz-wag-994
CAS# 130714-47-5
Instruction

Theoretical Analysis

MedKoo Cat#: 125480
Name: Sdz-wag-994
CAS#: 130714-47-5
Chemical Formula: C17H25N5O4
Exact Mass: 363.19
Molecular Weight: 363.420
Elemental Analysis: C, 56.19; H, 6.93; N, 19.27; O, 17.61

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: 130714-47-5; Sdz-wag-994; SDZ WAG 994; n-cyclohexyl-2'-o-methyladenosine; Adenosine, N-cyclohexyl-2'-O-methyl-

IUPAC/Chemical Name: (2R,3R,4R,5R)-5-(6-(cyclohexylamino)-9H-purin-9-yl)-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol

InChi Key: JAKAFSGZUXCHLF-LSCFUAHRSA-N

InChi Code: InChI=1S/C17H25N5O4/c1-25-14-13(24)11(7-23)26-17(14)22-9-20-12-15(18-8-19-16(12)22)21-10-5-3-2-4-6-10/h8-11,13-14,17,23-24H,2-7H2,1H3,(H,18,19,21)/t11-,13-,14-,17-/m1/s1

SMILES Code: CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N2C=NC3=C2N=CN=C3NC4CCCCC4

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 363.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Klaft ZJ, Duerrwald LM, Gerevich Z, Dulla CG. The adenosine A1 receptor
agonist WAG 994 suppresses acute kainic acid-induced status epilepticus in vivo.
Neuropharmacology. 2020 Oct 1;176:108213. doi: 10.1016/j.neuropharm.2020.108213.
Epub 2020 Jun 29. PMID: 32615188; PMCID: PMC7530074.

2: Cramer JA, Pasternak SJ, Athill LV. A tandem solid phase extraction,
reversed-phase HPLC method for determining SDZ WAG 994 in dog, monkey and rat
blood. J Pharm Biomed Anal. 1997 Mar;15(6):749-58. doi:
10.1016/s0731-7085(96)01899-7. PMID: 9172100.

3: Kashiwagi A. Rationale and hurdles of inhibitors of hepatic gluconeogenesis
in treatment of diabetes mellitus. Diabetes Res Clin Pract. 1995 Aug;28
Suppl:S195-200. doi: 10.1016/0168-8227(95)01079-s. PMID: 8529514.

4: Belardinelli L, Lu J, Dennis D, Martens J, Shryock JC. The cardiac effects of
a novel A1-adenosine receptor agonist in guinea pig isolated heart. J Pharmacol
Exp Ther. 1994 Dec;271(3):1371-82. PMID: 7996449.

5: Bertolet BD, Anand IS, Bryg RJ, Mohanty PK, Chatterjee K, Cohn JN, Khurmi NS,
Pepine CJ. Effects of A1 adenosine receptor agonism using
N6-cyclohexyl-2'-O-methyladenosine in patients with left ventricular
dysfunction. Circulation. 1996 Sep 15;94(6):1212-5. doi:
10.1161/01.cir.94.6.1212. PMID: 8822971.

6: Ishikawa J, Mitani H, Bandoh T, Kimura M, Totsuka T, Hayashi S. Hypoglycemic
and hypotensive effects of 6-cyclohexyl-2'-O-methyl-adenosine, an adenosine A1
receptor agonist, in spontaneously hypertensive rat complicated with
hyperglycemia. Diabetes Res Clin Pract. 1998 Jan;39(1):3-9. doi:
10.1016/s0168-8227(97)00116-2. PMID: 9597368.

7: Librán-Pérez M, Velasco C, Otero-Rodiño C, López-Patiño MA, Míguez JM,
Soengas JL. Metabolic response in liver and Brockmann bodies of rainbow trout to
inhibition of lipolysis; possible involvement of the hypothalamus-pituitary-
interrenal (HPI) axis. J Comp Physiol B. 2015 May;185(4):413-23. doi:
10.1007/s00360-015-0894-8. Epub 2015 Feb 10. PMID: 25666862.